Skip to content

The effect of remazolam on intraoperative hemodynamics in patients undergoing cardiac surgery under cardiopulmonary bypass

The effect of remazolam on intraoperative hemodynamics in patients undergoing cardiac surgery under cardiopulmonary bypass

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200060501
Enrollment
Unknown
Registered
2022-06-03
Start date
2022-06-12
Completion date
Unknown
Last updated
2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac surgery under cardiopulmonary bypass

Interventions

Treatment group:Ramazolam
Control group:Propofol

Sponsors

First Affiliated Hospital of Air Force Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-64 years old, undergoing elective extracorporeal circulation coronary artery bypass grafting, valve replacement or repair surgery, coronary artery bypass graft combined with valve replacement or repair surgery; 2. ASA grading II-IV; 3. NYHA grading II-III; 4. Sign the subject's informed consent form.

Exclusion criteria

Exclusion criteria: 1. There are known contraindications to the use of remazolam and propofol; 2. Preoperative ejection fraction < 35%; 3. Basal mean arterial pressure (MAP) before anesthesia < 65mmHg, basal heart rate < 50 beats/min; 4. Have a history of neuropsychiatric psychiatrics in the past or have recently taken drugs that affect the central nervous system; 5. Those who have participated in other clinical trials.

Design outcomes

Primary

MeasureTime frame
MAP-time integral;

Secondary

MeasureTime frame
To evaluate the effect of drugs on hemodynamics;To evaluate the correlative indexes of organ injury;To evaluate the effect of drugs on brain waves;

Countries

China

Contacts

Public ContactHou Lihong

First Affiliated Hospital of Air Force Military Medical University

909723907@qq.com+86 13991183806

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026